Skip to main content
. 2010 Feb 7;16(5):547–553. doi: 10.3748/wjg.v16.i5.547

Figure 4.

Figure 4

Individual and pooled relative risk and heterogeneity indicators for the outcome of “global or clinical improvement (A, B)” and “relief of abdominal pain (C, D)” in the studies considering mebeverine 200 mg compared to mebeverine 135 mg.